Categories
Announcements Find Funding

Research Matters

NIH Countermeasures Against Chemical Threats (CounterACT) Early-stage Investigator Research Award (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement is to recruit Early Stage Investigators to pursue research programs of interest to NIH Chemical Countermeasures Research Program under the NIH Countermeasures Against Chemical Threats grant/cooperative agreement program.

The purpose of this Funding Opportunity Announcement (FOA) is to recruit Early Stage Investigators (ESI) to pursue research programs of interest to NIH Chemical Countermeasures Research Program (CCRP) under the NIH Countermeasures Against Chemical Threats (CounterACT) grant/cooperative agreement program.

ESI CounterACT R21 projects may be exploratory, applied, proof of principle, or high risk-high impact research to discover safe and effective therapeutics to mitigate toxicities resulting from exposures to highly toxic chemicals.

A distinct feature for this FOA is that no preliminary data are required, expected, or encouraged. However, if available, minimal preliminary data are allowed. All preliminary data should be clearly marked and limited to one-half page, which may include one figure. Applications including preliminary data more than one-half page or more than one figure will be considered noncompliant with the FOA instructions and will not go forward to review.

Projects supported by this FOA will have an extended level of support (3 years) and are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive funding support from the NIH CounterACT programs or other related initiatives. Investigators that compete successfully for this R21 mechanism will not lose their ESI status.

Open date: June 27, 2021

More information